Skip to main content
. 2021 Jan 16;13(2):312. doi: 10.3390/cancers13020312

Figure 2.

Figure 2

Recognition of tumor cells by monoclonal antibodies (mAbs). Therapeutic mAbs can recognize tumor antigens and oncogenic peptide/MHC class I complexes on malignant cells. Receptor/IgG fusion proteins, such as NKG2D/Fc, target tumor-associated ligands MICA or MICB.